The newly released CRISPR and Cas Gene Market analysis report by Future Market Insights shows that global sales of CRISPR and Cas Gene Market in 2021 were held at US$ 1.8 Billion. With 30.2%, the projected market growth from 2023 to 2033 is expected to be significantly higher than the historical growth. Biomedical is expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 30.5% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global CRISPR and Cas Genes Market (2023) | USD 2.4 Billion |
| Global CRISPR and Cas Genes Market (2033) | USD 32.9 Billion |
| Global CRISPR and Cas Genes Market CAGR (2023 to 2033) | 30.2% |
| USA and Cas Genes Market CAGR (2023 to 2033) | 28.5% |
| Key Companies Profiled | AstraZeneca plc.; Addgene; Caribou Biosciences, Inc.; Cellectis; CRISPR Therapeutics; Editas Medicine, Inc.; 23andMe, Inc.; Color Genomics, Inc.; Myriad Genetics, Inc.; F. Hoffmann-La Roche AG; Bio-Rad Laboratories, Inc.; Quest Diagnostics; Air Methods; ALPHASTAR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the CRISPR and Cas Gene Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the CRISPR and Cas Gene Market increased at around 30.2% CAGR.
The approach is employed primarily to study the evolution of bacteria. Governments throughout the globe have promoted investments in genome editing developments, paving the path for the rise of the CRISPR and Cas Genes markets.
The invention of the Cas-9 technology is the most significant advancement in this discipline. This is a game-changing breakthrough in biomedical research. The use of CRISPR/Cas-9 focuses on somatic cell genome editing and intends to speed up therapy for various genetic illnesses.
Furthermore, the COVID-19 pandemic is expected to uncover credible uses of this approach to explain the mutation of the new coronavirus. CRISPR-based testing has been shown in studies to be more accurate than other approaches such as RT-PCR assays.
Furthermore, genome editing is expanding the potential to clarify genetics' role in diagnostics by enabling more precise cellular and animal models of disease processes.
Moreover, the recent creation of a flexible, democratized genome-engineering toolbox based on programmable targeting of CRISPR, and Cas systems has been spurred by the discovery and characterization of CRISPR and Cas Genes. The method is commonly employed in research to discover new therapy options for neurodegenerative illnesses. Advances in genome editing have permitted the use of CRISPR-Cas systems in diagnostics and the evaluation of evolutionary analyses in prokaryotes.
Furthermore, the market is being driven by the development of CRISPR-based diagnostic tests to overcome the timing and sample collection constraints for COVID-19 screening.
Lately, it was observed that research institutions and businesses are working hard to explore new horizons to implement the use of CRISPR and Cas Gene for commercial purposes, thereby it is expected that the demand for gene-editing patents will shoot up. Also, there has been a spike in the use of this technology for various medical and non-traditional applications, which will drive the demand for the CRISPR and Cas Gene market.
However, the expansion of the global CRISPR and Cas Gene market is projected to be restricted due to rising ethical and safety concerns regarding CRISPR and Cas Gene therapy for gene editing and the creation of genetically modified foods or organisms. The altering of the human germline is the primary ethical issue related to CRISPR technology. CRISPR technology is intended to correct a faulty human gene in order to treat specific diseases. Several organizations have expressed worry that employing CRISPR technology may alter humans' native DNA, which is immoral.
Principal Consultant
In 2021, North America held the largest share of the global CRISPR and Cas Gene market. Increased funding for research efforts for the prevention of chronic illnesses is expected to fuel the growth of the CRISPR and Cas Genes market in North America. Furthermore, positive efforts by the government and an increase in the number of research collaborations are likely to boost market expansion.
However, the market in Asia-Pacific is expected to expand at a high rate with China growing at a CAGR of over 35%. The need for genetically modified therapeutic alternatives for chronic diseases such as cancer is expected to boost the market's development prospects in the Asia Pacific.
The United States is expected to have the highest market of US$ 9.4 Billion by 2033. Due to favorable healthcare legislation, a high prevalence of chronic illnesses, and a developed healthcare sector, the market in the United States accounts for the largest share.
The market in the United Kingdom is expected to reach a valuation of US$ 2 Billion by 2032, growing at a CAGR of 34.8% from 2023 to 2033. The market is projected to gross an absolute dollar opportunity of US$ 1.9 Billion during the forecast period.
In Japan, the market is expected to reach a valuation of US$ 1.6 Billion by 2033. During the forecast period, the market in the country is expected to garner an absolute dollar opportunity of US$ 1.5 Billion, growing at a CAGR of 34.9%.
The market in South Korea is projected to grow at a CAGR of 30.1% from 2023 to 2033. During this period, the market is projected to witness an absolute dollar opportunity of US$ 683 Million and reach US$ 736 Million by 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
CRISPR and Cas Gene Products are expected to command the largest revenue as well as a CAGR of nearly 30%, during the forecast period. The availability of novel tools and CRISPR gene editing kits for gene modification investigations meets the increasing need for genome editing solutions.
The increased demand for genome editing solutions is met by the availability of novel tools and CRISPR gene kits, which helps in modifications Furthermore, higher R&D investments, as well as the introduction of novel applications, are expected to boost the market.
Since more gene-editing researchers are employing these technologies, the market is expected to generate higher revenue throughout the projected period. Cell line engineering services, on the other hand, are the most popular among CRISPR-based gene editing companies. This technology is being used by corporations to develop a range of CRISPR cell line models with distinct gene or locus-specific modifications.
Biomedical applications commanded the largest revenue as well as CAGR of 30.5%, during the forecast period. The growing usage of CRISPR gene-editing methods in numerous sectors of biological sciences has contributed significantly to the segment's high profitability.
Over the forecast period, extensive biomedical research is expected to boost the sector. Furthermore, the utilization of nano-carriers and the development of novel delivery systems have boosted the efficacy and distinctiveness of this technology significantly. The Cas9 nuclease's development allows for simple and accurate genome editing. As a result, the gene and cell therapy industries will have a direct impact on how CRISPR genome editing technology is used.
Some of the key players in the CRISPR and Cas Gene Market include AstraZeneca plc, Addgene, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Editas Medicine, Inc., 23andMe, Inc., Color Genomics, Inc., Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Quest Diagnostics, Air Methods, and ALPHASTAR.
Some of the recent developments of key CRISPR and Cas Gene providers are as follows:
Similarly, recent developments related to the company's CRISPR and Cas Gene services have been tracked by the team at Future Market Insights, which are available in the full report.
The global market is forecasted to follow a y-o-y growth rate of roughly 30.2% through 2033.
The overall market size projected to close on a valuation of US$ 32.9 billion by 2033.
Proliferation of research institutes has boosted the CRISPR and Cas gene demand.
The biomedical application segment commanded over 30% of the global market in 2022.
The United States leads in this technology and could have a US$ 9.4 billion market by 2033.
1. Executive Summary | CRISPR and Cas Gene Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Regulatory Landscape
3.3.1. By Key Regions
3.3.2. By Key Countries
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Kits & Enzymes
5.3.2. Libraries
5.3.3. Design Tool
5.3.4. Antibodies
5.3.5. Other products
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Service Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Service Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Type, 2023 to 2033
6.3.1. Cell Line Engineering
6.3.2. gRNA design
6.3.3. Microbial Gene Editing
6.3.4. DNA Synthesis
6.4. Y-o-Y Growth Trend Analysis By Service Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Service Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
7.3.1. Clinical
7.3.2. Financial
7.3.3. Operational & Administrative
7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033
8.3.1. Biotechnology & Pharmaceutical Companies
8.3.2. Academics & Government Research Institutes
8.3.3. Contract Research Organizations (CROs)
8.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. East Asia
9.3.5. South Asia
9.3.6. Oceania
9.3.7. Middle East and Africa(MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Product Type
10.2.3. By Service Type
10.2.4. By Application
10.2.5. By End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Service Type
10.3.4. By Application
10.3.5. By End Use
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Argentina
11.2.1.4. Rest of Latin America
11.2.2. By Product Type
11.2.3. By Service Type
11.2.4. By Application
11.2.5. By End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Service Type
11.3.4. By Application
11.3.5. By End Use
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. Italy
12.2.1.3. France
12.2.1.4. UK
12.2.1.5. Spain
12.2.1.6. Russia
12.2.1.7. BENELUX
12.2.1.8. Rest of Europe
12.2.2. By Product Type
12.2.3. By Service Type
12.2.4. By Application
12.2.5. By End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Service Type
12.3.4. By Application
12.3.5. By End Use
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product Type
13.2.3. By Service Type
13.2.4. By Application
13.2.5. By End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Service Type
13.3.4. By Application
13.3.5. By End Use
13.4. Key Takeaways
14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Thailand
14.2.1.3. Malaysia
14.2.1.4. Indonesia
14.2.1.5. Rest of South Asia
14.2.2. By Product Type
14.2.3. By Service Type
14.2.4. By Application
14.2.5. By End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Service Type
14.3.4. By Application
14.3.5. By End Use
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Product Type
15.2.3. By Service Type
15.2.4. By Application
15.2.5. By End Use
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Service Type
15.3.4. By Application
15.3.5. By End Use
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. Rest of Middle East and Africa(MEA)
16.2.2. By Product Type
16.2.3. By Service Type
16.2.4. By Application
16.2.5. By End Use
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product Type
16.3.3. By Service Type
16.3.4. By Application
16.3.5. By End Use
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Product Type
17.1.2.2. By Service Type
17.1.2.3. By Application
17.1.2.4. By End Use
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Product Type
17.2.2.2. By Service Type
17.2.2.3. By Application
17.2.2.4. By End Use
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Product Type
17.3.2.2. By Service Type
17.3.2.3. By Application
17.3.2.4. By End Use
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Product Type
17.4.2.2. By Service Type
17.4.2.3. By Application
17.4.2.4. By End Use
17.5. Argentina
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Product Type
17.5.2.2. By Service Type
17.5.2.3. By Application
17.5.2.4. By End Use
17.6. Germany
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Product Type
17.6.2.2. By Service Type
17.6.2.3. By Application
17.6.2.4. By End Use
17.7. Italy
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Product Type
17.7.2.2. By Service Type
17.7.2.3. By Application
17.7.2.4. By End Use
17.8. France
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Product Type
17.8.2.2. By Service Type
17.8.2.3. By Application
17.8.2.4. By End Use
17.9. UK
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Product Type
17.9.2.2. By Service Type
17.9.2.3. By Application
17.9.2.4. By End Use
17.10. Spain
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Product Type
17.10.2.2. By Service Type
17.10.2.3. By Application
17.10.2.4. By End Use
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Product Type
17.11.2.2. By Service Type
17.11.2.3. By Application
17.11.2.4. By End Use
17.12. BENELUX
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Product Type
17.12.2.2. By Service Type
17.12.2.3. By Application
17.12.2.4. By End Use
17.13. China
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Product Type
17.13.2.2. By Service Type
17.13.2.3. By Application
17.13.2.4. By End Use
17.14. Japan
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Product Type
17.14.2.2. By Service Type
17.14.2.3. By Application
17.14.2.4. By End Use
17.15. South Korea
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Product Type
17.15.2.2. By Service Type
17.15.2.3. By Application
17.15.2.4. By End Use
17.16. India
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Product Type
17.16.2.2. By Service Type
17.16.2.3. By Application
17.16.2.4. By End Use
17.17. Thailand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Product Type
17.17.2.2. By Service Type
17.17.2.3. By Application
17.17.2.4. By End Use
17.18. Malaysia
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Product Type
17.18.2.2. By Service Type
17.18.2.3. By Application
17.18.2.4. By End Use
17.19. Indonesia
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Product Type
17.19.2.2. By Service Type
17.19.2.3. By Application
17.19.2.4. By End Use
17.20. Australia
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Product Type
17.20.2.2. By Service Type
17.20.2.3. By Application
17.20.2.4. By End Use
17.21. New Zealand
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Product Type
17.21.2.2. By Service Type
17.21.2.3. By Application
17.21.2.4. By End Use
17.22. GCC Countries
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Product Type
17.22.2.2. By Service Type
17.22.2.3. By Application
17.22.2.4. By End Use
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Product Type
18.3.3. By Service Type
18.3.4. By Application
18.3.5. By End Use
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. AstraZeneca plc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. Addgene
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Caribou Biosciences, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. Cellectis
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. CRISPR Therapeutics
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Editas Medicine, Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. 23andMe, Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. Color Genomics, Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
19.1.9. Myriad Genetics, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.9.5.2. Product Strategy
19.1.9.5.3. Channel Strategy
19.1.10. F. Hoffmann-La Roche AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.10.5.2. Product Strategy
19.1.10.5.3. Channel Strategy
19.1.11. Bio-Rad Laboratories, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.11.5.2. Product Strategy
19.1.11.5.3. Channel Strategy
19.1.12. Quest Diagnostics
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.12.5.2. Product Strategy
19.1.12.5.3. Channel Strategy
19.1.13. Air Methods
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.13.5.2. Product Strategy
19.1.13.5.3. Channel Strategy
19.1.14. ALPHASTAR
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.14.5.2. Product Strategy
19.1.14.5.3. Channel Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
CRISPR and Cas Gene Market
